KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Expenses: 2014-2024

Historic Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to $503.9 million.

  • CRISPR Therapeutics AG's Operating Expenses rose 20.06% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $612.7 million, marking a year-over-year increase of 14.48%. This contributed to the annual value of $503.9 million for FY2024, which is 15.14% down from last year.
  • As of FY2024, CRISPR Therapeutics AG's Operating Expenses stood at $503.9 million, which was down 15.14% from $593.7 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Operating Expenses ranged from a high of $674.4 million in FY2022 and a low of $355.2 million during FY2020.
  • Over the past 3 years, CRISPR Therapeutics AG's median Operating Expenses value was $593.7 million (recorded in 2023), while the average stood at $590.7 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Operating Expenses spiked by 52.45% in 2021, and later decreased by 15.14% in 2024.
  • CRISPR Therapeutics AG's Operating Expenses (Yearly) stood at $355.2 million in 2020, then skyrocketed by 52.45% to $541.4 million in 2021, then rose by 24.55% to $674.4 million in 2022, then declined by 11.95% to $593.7 million in 2023, then dropped by 15.14% to $503.9 million in 2024.